Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 05:36:56 pm
73.55 EUR   -0.30%
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 SANOFI : FDA lifts clinical hold on fitusiran
12/15 SANOFI : FDA lifts clinical hold on fitusiran
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Positive results for DNA-based Zika Vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:11pm CET

All 40 healthy volunteers in the study developed Zika-specific antiboides after three doses, researchers said.

The companies GLS-5700 is a DNA-based vaccine that is made by reproducing sections of the Zika virus genome and loading them onto a plasmid, unlike standard vaccines that usually use inactivated or killed versions of a virus.

After the vaccine is injected into a patient, a device is used to generate electrical impulses that create small pores in cells that allow the DNA to get inside.

Sanofi ended development on its more traditional Zika vaccine last month, while Takeda is still working on its own product.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
12/15 SANOFI : Aquino not yet off the hook Richard Gordon
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 SANOFI : Solon wants Sanofi, DOH held liable for vaccine mess
12/15 NOBODY KNEW DENGVAXIA POSED RISKS : ex-president Aquino
12/15 SANOFI : Aquino confirms Paris meeting with Sanofi execs over vaccine supply
12/15 SANOFI : FDA lifts clinical hold on fitusiran
12/15 SANOFI : FDA lifts clinical hold on fitusiran
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Topline Pivotal Results..
12/15 REGENERON PHARMACEUTICALS : Collaboration Programs Highlighted During Sanofi Ana..
More news
News from SeekingAlpha
12/15 BIOTECH FORUM DAILY DIGEST : Impacts Of Tax Reform
12/15 FDA lifts clinical hold on Alnylam's fitusiran; shares up 6% premarket
12/14 Sanofi (SNY) Investor Presentation - Slideshow
12/14 Challenge of two Lantus patents commences
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
Financials (€)
Sales 2017 35 834 M
EBIT 2017 9 337 M
Net income 2017 8 158 M
Debt 2017 4 979 M
Yield 2017 4,10%
P/E ratio 2017 11,55
P/E ratio 2018 16,02
EV / Sales 2017 2,74x
EV / Sales 2018 2,69x
Capitalization 93 181 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 84,1 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.07%109 810
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759